Borrelia burgdorferi Antibodies, Total by ELISA, CSF
Ordering Recommendation

Use in conjunction with positive serologic testing for the workup of suspected acute Lyme neuroborreliosis. Do not order in the absence of clinical symptoms.

Semi-Quantitative Enzyme-Linked Immunosorbent Assay
Sun - Sat
1-3 days
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Specimen Preparation
Transfer 3 mL CSF to an ARUP Standard Transport Tube. (Min: 0.5 mL) 
Storage/Transport Temperature
Unacceptable Conditions
Contaminated, heat-inactivated, or hemolyzed specimens. 
Ambient: 8 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles) 
Reference Interval
0.99 LIV or lessNegative - Antibody to B. burgdorferi not detected.
1.00-1.20 LIVEquivocal - Repeat testing in 10-14 days may be helpful.
1.21 LIV or greaterPositive - Probable presence of antibody to B. burgdorferi detected.

Interpretive Data
The detection of antibodies to B. burgdorferi in cerebrospinal fluid may indicate central nervous system infection. However, consideration must be given to possible contamination by blood or transfer of serum antibodies across the blood-brain barrier.

Current CDC recommendations for the serologic diagnosis of Lyme disease are to screen with a polyvalent ELISA test and confirm equivocal and positive results with immunoblot. Both IgM and IgG immunoblots should be performed on samples less than 4 weeks after appearance of erythema migrans. Only IgG immunoblot should be performed on samples greater than 4 weeks after the disease onset. IgM immunoblot in the chronic stage is not recommended and does not aid in the diagnosis of neuroborreliosis or chronic Lyme disease. Please submit requests for appropriate immunoblot testing within 10 days.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Once this test is performed, if:
a) Negative - no further testing is done.
b) Positive or equivocal - Immunoblot testing will be performed on the original sample upon receiving a request. Sample will be held for 30 days only.
Hotline History
View Hotline History
Component Test Code*Component Chart NameLOINC
0099483Borrelia burgdorferi Abs, ELISA, CSF6318-0
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Lyme Antibodies, Total
  • Lyme Disease
  • Lyme Disease Ab CSF, ELISA